Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
SOLENO THERAPEUTICS INC (SLNO) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Termination of a Material Definitive Agreement, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"REDWOOD CITY, Calif"
08/08/2023 8-K Quarterly results
Docs: "Soleno Therapeutics, Inc. Condensed Consolidated Balance Sheets"
07/10/2023 8-K Investor presentation
Docs: "Presentation Materials"
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/09/2023 8-K Quarterly results
Docs: "REDWOOD CITY, Calif., May 9, 2023 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 and Recent Corporate Highlights"
05/03/2023 8-K Quarterly results
03/21/2023 8-K Quarterly results
Docs: "REDWOOD CITY, Calif., March 21, 2023 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2022. Fourth Quarter 2022 and Recent Corporate Highlights"
02/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2020 Inducement Equity Incentive Plan, as amended on February 17, 2023",
"2020 Inducement Equity Incentive Plan, as amended on February 17, 2023"
01/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/19/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
10/03/2022 8-K Quarterly results
08/25/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Certificate of Amendment to the Certificate of Incorporation",
"Certificate of Amendment to the Certificate of Incorporation"
08/10/2022 8-K Quarterly results
07/25/2022 8-K/A Quarterly results
07/20/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/30/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between Soleno Therapeutics, Inc. and Oppenheimer & Co. Inc",
"Form of Pre-Funded Warrant To Purchase Common Stock",
"Form of Common Warrant To Purchase Common Stock",
"Opinion of Wilson Sonsini Goodrich & Rosati, P.C",
"Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering"
03/28/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Soleno Therapeutics Announces Proposed Underwritten Public Offering REDWOOD CITY, Calif."
03/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
01/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/24/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome REDWOOD CITY, Calif., January 24, 2022 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S. Food and Drug Administration regarding the development of once-daily DCCR extended-release tablets for the treatment of Prader-Willi syndrome . On January 20, 2022, the Company received official meeting minutes from the December 21, 2021, Type C meeting with the FDA's Division of Psychiatry. The purpose of the meeting was to discuss the adequacy of the data submitted by Soleno to the FDA in October 2021 to support a potential New Drug Application subm..."
12/30/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Assignment Agreement effective as of December 28, 2021 by and among the Registrant and Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P",
"Assignment Agreement effective as of December 28, 2021 by and among the Registrant and Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P"
11/10/2021 8-K Quarterly results
Docs: "Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results REDWOOD CITY, Calif., November 10, 2021 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2021. “The recently announced top-line results from Soleno's ongoing open-label extension study evaluating DCCR for the treatment of Prader-Willi syndrome , and the comparison of these data to matched subjects from the PATH for PWS natural history study, highlight the compelling potential of this promising therapy in addressing the myriad physical and behavioral challenges faced by PWS patients and families..."
09/17/2021 8-K Quarterly results
07/28/2021 8-K Quarterly results
Docs: "Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results REDWOOD CITY, Calif., July 28, 2021 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2021. “The Soleno team remains focused on achieving regulatory approval for DCCR for the treatment of Prader-Willi syndrome, or PWS,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “We are continuing our dialogue with the U.S. Food and Drug Administration and, as recently announced, intend to submit the clinical study reports from DESTINY PWS and the C602 extension study, as well as addi..."
07/16/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Controlled Equity Offering Sales Agreement, by and between Soleno Therapeutics, Inc. and Cantor Fitzgerald & Co",
"Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation"
06/16/2021 8-K/A Quarterly results
06/03/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/14/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy